ino stock symbol: INO Nasdaq overview

INO (stock symbol)

The ino stock symbol refers to INO, the Nasdaq ticker for Inovio Pharmaceuticals, Inc. This article provides a clear, beginner‑friendly guide to the ino stock symbol, explaining the company behind the ticker, exchange and identifier details, price history and performance, financials, ownership structure, trading instruments, analyst coverage, material corporate actions, regulatory and legal risks, and recent news items that have moved the INO share price. Readers will learn how the ino stock symbol behaves in short and long timeframes, how liquidity and retail sentiment can affect trading, and where to find up‑to‑date market data or trade the equity (note: Bitget is presented as a recommended trading venue in this article).

Company overview

Inovio Pharmaceuticals, Inc. is a clinical‑stage biotechnology company focused on DNA‑based medicines and delivery technology, including DNA vaccines and immunotherapies. The firm develops synthetic DNA plasmids that encode antigens or therapeutic proteins and uses proprietary electroporation delivery devices to enhance cellular uptake of DNA therapies.

• Business model: Research, development and potential commercialization of DNA medicines and delivery systems. Revenue historically derives from collaborations, grants and occasional license fees, while product revenues are limited because INO has primarily been in clinical development.
• Primary products and pipeline: Development programs have included DNA vaccines for infectious diseases and DNA‑based immunotherapies for oncology and other indications. The company’s electroporation platform is a key technology for delivery.
• Headquarters and founding year: Inovio is headquartered in the United States and was founded in the 1980s (company roots and founding date tied to early DNA immunotherapy research; investors should refer to corporate filings for the exact founding year cited by the company).

Understanding the ino stock symbol begins with recognizing that INO represents a research‑heavy, clinical‑stage biotech issuer with product risk and development milestones that drive valuation more than recurring revenue.

Ticker and exchange information

• Stock symbol: INO (the ino stock symbol used in US equities markets).
• Primary exchange: Nasdaq (United States). The ino stock symbol trades on Nasdaq under the INO ticker.
• Trading currency: US dollars (USD).
• Identifiers: INO is registered for US equity trading; investors can locate company filings under the issuer name and find ISIN and CUSIP identifiers in the company’s investor relations or SEC filings. For the most recent ISIN and CUSIP, consult the company’s investor relations page or SEC submissions.
• Typical trading hours: Regular Nasdaq trading hours are 9:30 AM to 4:00 PM Eastern Time on US market trading days. Pre‑market and after‑hours trading sessions may provide additional liquidity but with typically lower volume and higher spreads; the ino stock symbol can display notable moves in extended sessions around news events.
• Market microstructure notes: As a Nasdaq‑listed equity, INO is subject to Nasdaq listing rules and market structure practices, including electronic order routing, market makers and centralized limit order book execution. For retail traders, trading INO on margin or via derivatives is governed by brokerage rules and platform availability.

For investors seeking to trade the ino stock symbol, Bitget provides access to US equities and market data (where available) and offers custody/wallet options for crypto; readers who prefer a single‑platform experience can explore Bitget’s trading features and Bitget Wallet for related workflows.

Historical background and corporate milestones

This section summarizes chronological milestones tied to the company and events that historically affected the ino stock symbol.

• Founding and early R&D: The company’s scientific origins date back to early DNA vaccine research; early milestones were centered on platform development and preclinical proofs of concept.
• Clinical development milestones: Over time, Inovio advanced multiple candidates into human studies. Clinical trial launches and readouts for key programs have historically been major catalysts for the ino stock symbol, with positive data often producing rapid rallies and negative results triggering steep declines.
• COVID‑19 era developments: Inovio pursued a DNA‑based COVID‑19 vaccine candidate during the pandemic, generating significant investor interest. Trial updates, regulatory interactions and partnership announcements during that period led to high volatility in the ino stock symbol.
• Strategic partnerships and collaborations: The company has announced collaborations, licensing agreements and government grants at various times. Partnerships with research institutions or government funding milestones frequently influenced investor sentiment and trading volume for the ino stock symbol.
• Regulatory submissions: Key regulatory filings—such as investigational new drug (IND) submissions and subsequent trial authorizations—represent important milestones that can move the ino stock symbol.
• Index inclusions: Periodic index reconstitution (for example, small‑cap indices) could temporarily affect demand for INO shares; historically, inclusion or exclusion from indices like small‑cap benchmarks or Russell rebalances has had short‑term liquidity implications.
• Major management changes: CEO and executive leadership changes, particularly when timed with strategic shifts (e.g., refocus of pipeline), have been material events for holders of the ino stock symbol.
• Corporate restructuring and capital raises: Equity financings and share‑related corporate actions (covered later) often reflect strategy and funding needs and have been central drivers of share dilution and price action for the ino stock symbol.

Investors following the ino stock symbol should track company press releases and SEC filings to monitor milestone progress and their likely market impact.

Price history and market performance

Intraday and short‑term performance

The ino stock symbol is known for episodes of elevated intraday volatility, particularly around product trial readouts, regulatory news or partnering announcements. Typical intraday characteristics include:

• Wider bid‑ask spreads during low‑volume sessions and after hours.
• Price gaps at the open following overnight news; sizeable after‑hours moves can carry into the next trading day.
• Short‑term traders often see rapid percentage moves; stop orders and options expiries can exacerbate short windows of movement for the ino stock symbol.

Retail interest and social sentiment spikes have historically led to sudden intraday volume surges on the ino stock symbol, increasing both opportunity and execution risk.

Long‑term price history

Over multi‑year horizons, INO’s share price has been shaped by clinical outcomes, financing activity and sector‑wide biotech sentiment:

• Notable peaks: Positive trial results, promising scientific announcements or heightened pandemic‑era interest led to sharp rallies in INO at times. These peaks were often transient unless followed by confirmatory commercial or regulatory progress.
• Notable troughs: Failed trials, regulatory setbacks, delayed programs, or large equity raises have driven extended declines in the ino stock symbol.
• All‑time highs and lows: Historical record highs and lows reflect company‑specific catalysts and broader biotech cycles; investors should verify the latest historical high/low via market data providers.

Substantial long‑term returns in either direction have been common for the ino stock symbol, in line with other clinical‑stage biotech equities whose valuations hinge on binary trial outcomes and capital markets activity.

Key price metrics

As of the most recent public data reporting window, market metrics for the ino stock symbol included quantifiable ranges that capture typical investor expectations. Readers should consult live market pages for the exact, up‑to‑the‑minute figures. Example reference metrics (reported ranges as of mid‑year reporting windows):

• 52‑week range: INO’s 52‑week high and low can span large percentage differences in biotech names; check a market data provider for the precise 52‑week high/low for the ino stock symbol as of your query date.
• Recent closing price and market cap ranges: Market capitalization for companies like Inovio has historically varied from low‑hundreds of millions of USD to higher figures depending on share price swings. For a specific snapshot of the ino stock symbol’s market cap and recent closing price, consult a current market quote.
• Average daily volume: Average volume can vary materially over time. At times of renewed clinical interest or retail attention, average daily volume for the ino stock symbol can spike well above baseline levels.

Because these metrics change daily, the ino stock symbol requires real‑time checks; Bitget market data pages and other reputable providers offer live quotes and historical charts for verification.

Financials and key metrics

When evaluating the ino stock symbol, investors typically focus on a handful of financial metrics that reflect the company’s development‑stage profile:

• Revenue: As a clinical‑stage biotech, Inovio’s revenue has historically been limited and often driven by collaboration payments, grants or milestone receipts rather than product sales.
• Net income (profit/loss): The company has typically reported operating losses as R&D and SG&A expenses exceed revenue during development phases. Net losses are common and expected for the ino stock symbol until a product achieves commercialization.
• EPS (TTM): Trailing‑twelve‑month EPS is often negative for development‑stage biotech companies; INO’s EPS (TTM) has reflected net losses.
• Cash position: Cash and short‑term investments are critical metrics; the company’s cash runway—reported in SEC filings—determines near‑term financing needs. Capital raises and timing of expenses tied to trials will drive cash‑balance trends important to holders of the ino stock symbol.
• Valuation ratios: Traditional ratios like P/E may be not meaningful because of negative earnings. Alternative metrics such as enterprise value (EV) to prospective revenue (if applicable) or cash per share and burn rate are more informative for INO.

Summary assessment: The financial condition of the issuer behind the ino stock symbol is best evaluated by reviewing the most recent quarterly and annual SEC filings for up‑to‑date revenue, cash and cash‑burn metrics. Given cyclical financing activity in biotech, the ino stock symbol’s valuation is often forward‑looking and sensitive to trial milestones.

Ownership, float and institutional holders

Ownership structure and float characteristics influence liquidity and volatility for the ino stock symbol.

• Shares outstanding and float: The total shares outstanding and free float (shares available for public trading) determine how much supply is available to meet demand. The ino stock symbol has experienced changes to shares outstanding over time due to equity raises and option exercises.
• Major institutional holders: Institutional ownership can include mutual funds, hedge funds and healthcare‑focused investors. High institutional ownership may provide stable base demand; conversely, concentrated ownership can lead to larger directional moves when institutions trade.
• Insider ownership: Executive and board ownership trends are relevant for corporate governance and alignment of interests. Insider selling or purchasing is often closely watched by investors in the ino stock symbol.
• Impact on liquidity and volatility: Low free float or concentrated holdings can amplify price moves for the ino stock symbol, while broad institutional participation can increase average volume and reduce volatility in some periods.

Investors can view current institutional and insider ownership metrics in the company’s investor relations disclosures and market data platforms for the latest figures tied to the ino stock symbol.

Trading instruments and market data

Shares and liquidity

• Average daily volume and liquidity: The ino stock symbol’s typical daily volume varies by news cycle. During major announcements, volume can spike substantially above historical averages, increasing both opportunity and price impact.
• Shares outstanding and free float: Equity financing events (covered later) have changed the share count historically; free float reflects shares available to public investors and influences spread and trade execution quality for the ino stock symbol.
• Borrow rates and short interest: For traders who short the ino stock symbol, borrow availability and cost can be important. Short interest—expressed as a percentage of float or as days to cover—can contribute to squeeze dynamics if positions become crowded.
• Trading patterns: Common patterns include volatility clustering around trial readouts and earnings or company‑specific filings. Retail traders often concentrate activity around headline events, causing intraday surges in liquidity.

Options market

• Availability of listed options: Options availability depends on exchange listings and market demand. At times, INO has had listed options with varying maturities and strikes.
• Typical open interest: Open interest levels change with market interest and can be concentrated near strike prices that attract hedging or directional speculation. Options activity can amplify price moves for the ino stock symbol, particularly when expiring near catalysts.
• Impact on price: Large options positions or concentrated open interest at specific strikes have occasionally influenced short‑term price behavior for biotech tickers like INO as participants hedge delta exposure.

Alternative data and social sentiment

• Retail interest: Social platforms and retail brokerage metrics can illustrate retail engagement. Spikes in retail interest on platforms such as StockTwits and retail brokerage flows have previously coincided with elevated trading in the ino stock symbol.
• Community influence: Charting communities, biotech forums and investor threads can drive narratives that become self‑reinforcing in the short term, affecting intraday liquidity and sentiment for the ino stock symbol.
• Sentiment indicators: Search volume, social mentions and unusual options activity are alternative datasets investors watch for early signals about interest in the ino stock symbol.

Note: Bitget provides market data tools and social sentiment panels that users can leverage when monitoring the ino stock symbol and related activity.

Analyst coverage and consensus

Analyst coverage for the ino stock symbol tends to come from specialized healthcare and biotech analysts rather than broad‑based coverage. Key points:

• Coverage mix: Coverage levels can fluctuate; a small number of sell‑side analysts typically issue coverage, offering buy/hold/sell ratings and target prices for the ino stock symbol.
• Ratings breakdowns: The proportion of buy/hold/sell ratings evolves with trial and regulatory news; analysts revise targets as clinical data and company guidance emerge.
• Representative price targets: Price targets historically reflect analysts’ estimates of probability‑weighted outcomes for pipeline assets. Targets may vary widely across analysts given binary clinical outcomes.
• Changes over time: As programs progress or setbacks occur, analyst coverage can expand or contract; significant clinical readouts often prompt coverage changes and target updates for the ino stock symbol.

For up‑to‑date analyst sentiment and consensus metrics on the ino stock symbol, consult market data services and broker research notes.

Corporate actions and capital markets activity

Capital markets events are central to understanding share count dynamics for the ino stock symbol.

• Secondary offerings and share issuances: As a development‑stage biotech, Inovio has periodically raised capital through equity offerings or registered direct placements. These actions increase share count and can dilute existing shareholders, often causing negative price pressure for the ino stock symbol around announcement dates.
• Stock splits and reverse splits: Any stock split or reverse split would directly affect the per‑share price and share count for the ino stock symbol; investors should check company records for history of split activity.
• Delistings or uplistings: As a Nasdaq‑listed company, INO has generally maintained its listing; any material listing action (uplisting to a different tier or delisting) would be disclosed in company filings and by the exchange and would have material implications for the ino stock symbol.
• Convertible securities and warrants: Issuance of convertible debt or warrants can lead to future dilution when converted or exercised; these instruments are commonly used in biotech financing and can be drivers of share‑count expansion for the ino stock symbol.

Carefully review SEC filings and company press releases to understand the full capital structure when evaluating the ino stock symbol.

Legal, regulatory and risk events

Material legal and regulatory events have historically affected the ino stock symbol:

• Clinical trial setbacks: Negative safety signals or failed efficacy endpoints in pivotal trials are principal risk drivers for the ino stock symbol and can cause rapid declines.
• Regulatory interactions: Delays, requests for additional data, or complete response letters from regulatory agencies have material impact on the ino stock symbol’s prospects.
• Lawsuits and class actions: Like other public companies, Inovio has faced legal claims at times. Material litigation or class action suits related to corporate disclosures, trial conduct or other matters can affect investor sentiment and the ino stock symbol.
• Compliance and manufacturing risks: Biotech companies face manufacturing quality and compliance risks; material issues can delay filings and impact the ino stock symbol.

All of the above are non‑exhaustive; prospective holders of the ino stock symbol should read risk disclosures in the company’s SEC filings and public statements.

Notable news and events affecting the INO ticker

Stay current: headline events such as clinical trial readouts, regulatory filings, partnership deals, capital raises, and management changes commonly move the ino stock symbol. As with any clinical‑stage biotechnology equity, the market reacts quickly to new information.

• Dated reporting example: As of 2024‑06‑01, according to a major market data provider, the ino stock symbol showed elevated trading volume following an operational update from the company (source: Yahoo Finance reported snapshot on that date). Readers should verify the latest news feed for subsequent events that may have changed price or liquidity for the ino stock symbol.

When breaking news occurs, expect intraday and multi‑day volatility in the ino stock symbol and consult official company releases and SEC filings for authoritative details.

Related tickers and potential confusion

• Ticker clarification: The ino stock symbol specifically refers to Inovio Pharmaceuticals, Inc. on the Nasdaq exchange.
• Avoiding confusion: Similar letter combinations can appear in other contexts (for example, stock tickers in other markets, cryptocurrency token symbols, or company abbreviations). In the US equities context, the ino stock symbol should not be confused with tokens or non‑equity assets.
• Crypto and non‑equity usages: If you encounter "INO" outside of Nasdaq equity listings, confirm the asset class and trading venue—this article focuses exclusively on the ino stock symbol as a publicly traded equity.

See also

• Nasdaq and US equity market structure
• Basics of biotech investing and clinical trial phases
• DNA vaccine technology and electroporation delivery
• Comparative tickers in the biotechnology sector for benchmarking

References

The following sources were used to compile the information above. Each entry lists the source name and the relevant page or report title for verification; consult these providers for current numerical data and full documents.

• Yahoo Finance — INO Stock Quote and Profile (search for INO profile on Yahoo Finance). Report snapshots cited for trading metrics as of 2024‑06‑01.
• Nasdaq — INO Company Listing and Market Data (Nasdaq company page for Inovio Pharmaceuticals).
• Inovio Pharmaceuticals — Investor Relations and SEC Filings (company investor relations announcements and filings submitted to the SEC).
• SEC EDGAR — Company Filings for Inovio Pharmaceuticals (periodic reports, quarterly and annual filings).
• StockTwits — INO Feed (retail sentiment and social activity monitoring for the ino stock symbol).
• TradingView — INO Charting and Historical Data (historical price charts and technical snapshots for INO).
• Macrotrends — INO Historical Price and Financial Metrics (historical series for long‑term performance and ratios).
• Major market data providers (e.g., financial news pages and market aggregator snapshots used to reference ranges and observed trading behavior for the ino stock symbol).

Note: The references above identify the provider and page title for verification. For the most current data on the ino stock symbol, consult live quotes and the company’s official SEC filings.

External links

• Inovio Pharmaceuticals — Investor Relations (company website and investor relations portal).
• SEC EDGAR — Inovio Pharmaceuticals filings (company filings for authoritative disclosure).
• Market data pages — INO historical price and quote pages (use any major market data provider to view live INO quotes and charts).

Further exploration and live monitoring

Readers who want to follow the ino stock symbol in real time should use reputable market data services and review the company’s investor relations announcements and SEC filings. For trading access and integrated tools, consider Bitget’s trading platform and Bitget Wallet for custody and trade workflow support. Bitget provides market data, order execution tools and research resources that can help users monitor the ino stock symbol and related biotech tickers.

This overview focuses exclusively on the ino stock symbol as a US‑listed equity and does not address unrelated uses of the string "ino" outside financial markets. For investment decisions, rely on up‑to‑date data and official filings; this article is informational, not investment advice.

Want to track the ino stock symbol more closely? Explore Bitget’s market data tools, sign up for company alerts on the issuer’s investor relations page, and review the latest SEC filings for primary source disclosures.